$-0.01
(Market cap
$7 Mln
Recently Viewed
Clear AllMarket cap
$7 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
Industry P/E
24.64
EV/EBITDA
-12
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
10,735,649
CFO
$-35.35 Mln
EBITDA
$-75.53 Mln
Net Profit
$-75.30 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PharmaCyte Biotech Inc (PMCB)
| -7.2 | -10.8 | -27.0 | -44.0 | -38.8 | -52.3 | -39.2 |
|
BSE Sensex*
| -8.4 | 0.0 | -7.2 | 5.0 | 9.0 | 9.4 | 12.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
PharmaCyte Biotech Inc (PMCB)
| -53.9 | -27.1 | -26.3 | 17.2 | -75.1 | -83.5 | 9.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based... on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Read more
Interim CEO, President & Director
Mr. Joshua N. Silverman
Interim CEO, President & Director
Mr. Joshua N. Silverman
Headquarters
Las Vegas, NV
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of PharmaCyte Biotech Inc (PMCB) is $0.67 (NASDAQ) as of 09-Apr-2026 16:06 EDT. PharmaCyte Biotech Inc (PMCB) has given a return of -38.79% in the last 3 years.
Since, TTM earnings of PharmaCyte Biotech Inc (PMCB) is negative, P/E ratio is not available.
The P/B ratio of PharmaCyte Biotech Inc (PMCB) is 0.19 times as on 02-Apr-2026, a 97 discount to its peers’ median range of 6.03 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of PharmaCyte Biotech Inc (PMCB) are Rs 1.51 and Rs 0.63 as of 10-Apr-2026.
PharmaCyte Biotech Inc (PMCB) has a market capitalisation of $ 7 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in PharmaCyte Biotech Inc (PMCB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.